Survodutide is a novel GLP-1/glucagon dual agonist, representing an evolving class of medications. This page compares Survodutide with established GLP-1 receptor agonists such as Semaglutide (Wegovy), Tirzepatide (Zepbound), and Liraglutide (Saxenda, Victoza). Its dual mechanism of action targets both GLP-1 and glucagon receptors, potentially offering distinct metabolic effects.
Survodutide Alternatives: How It Compares to Other GLP-1-Based Therapies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 4/6 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape features established treatments such as Liraglutide (Saxenda, Victoza), approved in 2010, and Semaglutide (Wegovy), approved in 2017. Pipeline drugs Retatrutide and Mazdutide are currently in Phase 3, approximately 1-2 years behind, while Survodutide does not have an approval date.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Survodutide | GLP-1/glucagon dual agonist | — | Investigational | Pipeline | — | — |
| Liraglutide (Saxenda, Victoza) | GLP-1 receptor agonist | type 2 diabetes, obesity, cardiovascular risk reduction | 3.0 mg once daily | 2014 | -7.46% @ 56 weeks | $16k |
| Semaglutide (Wegovy) | GLP-1 receptor agonist | chronic weight management, type-2 diabetes (Ozempic), cardiovascular risk reduction | 2.4 mg SC weekly (escalation from 0.25 mg over 16 weeks) | 2021 | -14.9% @ week 68 | $16k |
| Tirzepatide (Zepbound) | GIP/GLP-1 dual receptor agonist | chronic weight management, type-2 diabetes (Mounjaro), obstructive sleep apnea | 5–15 mg SC weekly (titration) | 2023 | -22.5% @ week 72 | $14k |
| Retatrutide | GLP-1/GIP/glucagon triple agonist | — | Investigational | Pipeline | — | — |
| Mazdutide (Xinermei) | GLP-1/GCGR dual agonist | — | — | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Weight % change; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for obesity specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Survodutide vs Semaglutide (Wegovy)
No head-to-head Phase-3 trial directly compares Survodutide with Semaglutide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Survodutide vs Tirzepatide (Zepbound)
No head-to-head Phase-3 trial directly compares Survodutide with Tirzepatide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Survodutide vs Liraglutide (Saxenda, Victoza)
No head-to-head Phase-3 trial directly compares Survodutide with Liraglutide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Among investigational agents in active Phase 3 development, Retatrutide from Eli Lilly and Company is a triple GIP/GLP-1/glucagon receptor agonist. Its lead Phase 3 trial is registered under NCT05931367. Also in active Phase 3 development is Mazdutide, a GLP-1/glucagon dual agonist sponsored by Innovent Biologics (Suzhou) Co. Ltd., with its lead trial identified as NCT05607680.
These agents represent advancements in the multi-agonist class for metabolic disorders. While Survodutide, another GLP-1/glucagon dual agonist, is also in advanced development, Retatrutide and Mazdutide are progressing through their respective Phase 3 programs, potentially following a similar timeline, with some potentially being 1-2 years behind in their clinical development trajectory.
Choosing between Survodutide and its alternatives
Survodutide, as a GLP-1/glucagon dual agonist, introduces a distinct mechanism of action compared to agents solely targeting GLP-1 receptors. This dual agonism may offer a differentiated approach for some patients seeking metabolic benefits beyond GLP-1 agonism alone, potentially influencing its selection in specific clinical scenarios.
For other patients, established GLP-1-based therapies may be considered based on their demonstrated efficacy and dosing schedules. Semaglutide (Wegovy), a GLP-1 receptor agonist, has demonstrated a mean weight reduction of -14.9% at week 68 with a 2.4 mg weekly subcutaneous dose. Tirzepatide (Zepbound), a GIP/GLP-1 dual receptor agonist, showed a mean weight reduction of -22.5% at week 72 with weekly doses ranging from 5–15 mg. Liraglutide (Saxenda, Victoza), also a GLP-1 receptor agonist, achieved a mean weight reduction of -7.46% at 56 weeks with a 3.0 mg once daily dose. These agents offer varying efficacy profiles, dosing frequencies, and established safety records, which may influence clinical choice, alongside considerations like cost or specific patient comorbidities.
This information is not medical advice; clinical decisions belong with the prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
survodutidesurvodutide alternativesalternativescomparisonobesitysurvodutide-glp1-glucagon-obesitysurvodutide vs semaglutidesurvodutide vs tirzepatidesurvodutide vs liraglutidesurvodutide vs retatrutidesurvodutide vs mazdutide